RT Journal Article
SR Electronic
T1 Longitudinal analysis of antibody responses to the Pfizer BNT162b2 vaccine in Patients Undergoing Maintenance Hemodialysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.20.21260849
DO 10.1101/2021.07.20.21260849
A1 André Weigert
A1 Marie-Louise Bergman
A1 Lígia Gonçalves
A1 Iolanda Godinho
A1 Nádia Duarte
A1 Rita Abrantes
A1 Patrícia Borges
A1 Ana Brennand
A1 Vanessa Malheiro
A1 Paula Matoso
A1 Onome Akpogheneta
A1 Lindsay Kosack
A1 Pedro Cruz
A1 Estela Nogueira
A1 Magda Pereira
A1 Ana Ferreira
A1 Marco Marques
A1 Telmo Nunes
A1 João Viana
A1 Jocelyne Demengeot
A1 Carlos Penha-Gonçalves
YR 2021
UL http://medrxiv.org/content/early/2021/10/04/2021.07.20.21260849.abstract
AB Background Hemodialyzed patients are at higher risk for COVID-19 and were prioritized in the Portuguese vaccination campaignMethods We performed a prospective, longitudinal, cohort analysis of 143 patients on hemodialysis and 143 age-matched controls along BTN162b2 vaccination. ELISA quantified anti-full-length Spike IgG, IgM and IgA levels prior to the first vaccine dose (t0); 3 weeks later (second dose, t1); and 3 weeks later (t2); 127 patients were re-evaluated140 (t3) and 180 days (t4) after the first dose.Results Seroconversion at t1 was remarkably low in patients, with positivity for anti-spike IgG, IgM and IgA antibodies of 29.4%, 12% and 41%, respectively, increasing to 90.9% (IgG) and 83.9% (IgA) in t2, (IgM remained unchanged). Below 70 years of age anti-spike IgG levels at t1 were significantly lower compared to age-matched controls and showed a profile similar to older individuals. Immunosuppression was associated with lower antibody responses (p=0.005 at t1; p=0.008 at t2). Previous unresponsiveness to hepatitis B vaccination (75/129, 58% of patients negative for anti-HBs antibodies) did not correlate with humoral unresponsiveness to BTN162b2. Anti-spike IgG, IgM and IgA positivity and antibody levels significantly decay at t3, with IgG levels showing further waning at t4.Conclusions The large majority of hemodialyzed patients showed IgG seroconversion upon BNT162b2 mRNA vaccination, albeit a sizable proportion of patients presented poor responses. Follow-up of antibody responses 180 days post vaccination unveiled significant decay of anti-spike antibodies and warrant close monitoring of COVID-19 infection and further studies on reinforced vaccination schedules in patients undergoing maintenance hemodialysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPart of the laboratory evaluation was possible due to the use of research Funds from Davita Portugal. This work benefited from COVID-19 emergency funds 2020 from Calouste Gulbenkian Foundation and from Oeiras and Almeirim city councils. It was also supported by the Science and Technology Foundation, Ministry of Education and Science (FCT, Portugal) through the Project 754-Research4COVID-19 2nd edition.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics committee of Davita in Portugal in compliance with the Declaration of Helsinki, and follows international and national guidelines for health data protection. All participants provided informed consent to take part in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request